Aveuglement

Blinding reduces bias and increases the validity of trial outcomes by hiding treatment information from patients, physicians, data analysts, and other personnel. This prevents false reporting from participants who might believe they received treatment due to the placebo effect, and stops researchers from introducing bias through their expectations or observations.

The placebo effect is a psychological phenomenon where untreated subjects falsely believe they received actual treatment and report improved symptoms. Blinding counteracts this by administering a placebo or dummy treatment alongside the test treatment, preventing participants from knowing whether they received the active intervention or control.

In single-blind studies, only patients are unaware whether they received a placebo or actual treatment. Double-blind research hides treatment information from both patients and physicians, eliminating bias from both groups and preventing physicians from reporting biased observations based on their treatment preferences.

Triple-blind studies hide treatment information from patients, physicians, and data analysts. This comprehensive blinding approach prevents bias at every stage of the trial, ensuring that those analyzing and interpreting results remain unaware of which participants received the active treatment versus the placebo.

Controls in experiments establish a baseline by administering placebo treatment to a control group, which cannot influence the response variable. When combined with blinding, controls help researchers isolate the true effects of the active treatment by balancing the effects of being in an experiment with the effects of the active treatments.

Blinding can be applied to all people involved in clinical trials, including subjects, clinicians, data collectors, outcome adjudicators, and data analysts. The extent of blinding depends on the trial design, with single, double, and triple-blind approaches offering increasing levels of bias protection across different personnel.

The power of suggestion relies on participants believing they received an active treatment. When participants know they are receiving a placebo with no actual medication, this belief is eliminated, and the psychological mechanism driving symptom improvement disappears. Blinding preserves the power of suggestion by keeping participants unaware of their treatment status.